Latest News

Entrepreneur in Residence (EIR) Opportunity in Nanomedicine

September 28, 2022 /in Latest News

Entrepreneur in Residence (EIR) Opportunity : Biomedical Tech Entrepreneur Needed to Lead Company Formation in Nanomedicine

Do you have a passion for seeing research discoveries become life-saving reality? Do you have what it takes to drive winning partnerships to help create a healthier world? Could you lead a global-level new venture opportunity through to completion? Do you bring a track-record of success commercializing state-of-the-art biomedical technologies?

Read on to learn more about this joint opportunity from University Health Network/Toronto Innovation Acceleration Partners (TIAP). 


Read More

Calling All UHN Inventors! Inventor of the Year Award Nominations are Open.

July 28, 2022 /in Latest News

We are pleased to invite nominations for the 19th Annual Inventor of the Year Award (IOTY)

Sponsored by Commercialization at UHN, the Inventor of the Year Award recognizes an individual or team at UHN whose invention has made a substantial and noteworthy commercialization contribution leading to a healthier world.

Every day, new discoveries are made across the UHN campus that will impact the lives of Canadians and the global community. As UHN’s catalyst for the translation of research, discovery and clinical innovation into products and partnerships for a healthier world, we are...

Read More

Welcome, Robert Ciriello!

July 19, 2022 /in Latest News

UHN Commercialization welcomes Robert Ciriello, Business Development and Commercialization Principal – Data, Digital and Artificial Intelligence


We are pleased to announce the arrival of Robert Ciriello, who joins us in the role of Principal, Business Development and Commercialization, Data, Digital, and Artificial Intelligence and will lead the development of UHN’s Data, Digital and AI commercialization strategy, acting as the institutional owner of this immense and high-potential portfolio. In his new role, Robert...

Read More

Banding together for pandemic research

June 15, 2022 /in Latest News

Pandemic catalyzes innovative approach to accelerate Canada’s COVID-19 research efforts

The COVID-19 pandemic has had a profound effect on the world, and academic research institutions have certainly felt its impacts, pivoting to adjust to a new normal with downgraded on-site activities. While the pandemic brought its share of constraints on research activity, it also created new opportunities for innovative collaboration, catalyzing research institutions across the country to work better together. 

Thanks to a UHN-led collaboration, research involving biospecimens – e.g. samples of material, such as blood, tissue, or cell lines – as...

Read More

Welcome, Laura McLachlan!

May 31, 2022 /in Latest News

UHN Commercialization welcomes Laura McLachlan, our new Licensing & Commercialization Professional, Biomaterials and Clinical Tools


The UHN Commercialization team welcomes Laura McLachlan, our new Licensing & Commercialization Professional, Biomaterials and Clinical Tools.

Laura joined us in January of 2022. In this role, she is responsible for driving the growth of our broad non-exclusive licensing portfolio, working to maximize the...

Read More

Welcome, Allan DeBono!

May 10, 2022 /in Latest News

Allan DeBono joins us in the role of Licensing and Commercialization Professional, PM Cancer Centre

We are pleased to announce the arrival of Allan DeBono, who joins us in the role of Licensing and Commercialization Professional, supporting the commercialization of Princess Margaret (PM) Cancer Centre’s extensive research portfolio.

Allan is a cell and molecular...

Read More

Welcome, Erno Wienholds!

April 19, 2022 /in Latest News

Erno Wienholds joins us in the role of Licensing and Commercialization Professional, PM Cancer Centre


We are pleased to welcome one of our newest team members, Erno Wienholds, who joins us in the role of Licensing and Commercialization Professional, supporting the commercialization of Princess Margaret (PM) Cancer Centre’s extensive research portfolio.

Erno is an accomplished biomedical...

Read More

We are growing!

April 14, 2022 /in Latest News

Do you have a passion for seeing research discoveries become life-saving reality? Do you have what it takes to drive winning partnerships with industry to help create a healthier world?

Join the #1 institution in Canada for research commercialization and work with some of the best and brightest in the field!

We are looking for several experts to join our team. Interested in helping us fulfill our...

Read More

Accelerating Technology in Health

April 08, 2022 /in Latest News

Dr. Keshavjee named Scientific Director of Techna and Chief of Clinical Innovation at UHN.

A new era in commercialization at UHN has arrived! Commercialization at UHN congratulates Dr. Keshavjee in his new role created to advance the commercialization of scientific discoveries to the bedside to improve tomorrow’s health care.

UHN is pleased to announce that Dr. Shaf Keshavjee has been named the new Techna...

Read More

Discovery behind blockbuster Pfizer-Trillium deal started at UHN and SickKids

March 22, 2022 /in Latest News

L to R: Dr. John Dick, Senior Scientist at the Princess Margaret Cancer Centre and McEwen Stem Cell Institute; Dr. Jayne Danska, Senior Scientist in the Genetics & Genome Biology program and Associate Chief, Faculty Development and Diversity at SickKids Research Institute; Dr. Jean Wang, Clinician Scientist and Staff Hematologist at the Princess Margaret Cancer Centre


A cancer research discovery made at the University Health Network and The Hospital for Sick Children has...

Read More

Another UHN Start-Up Goes Public!

February 24, 2022 /in Latest News

MyndTec Inc. officially listed and began trading shares on the CSE on February 24th, 2022

Founded in 2012 based on UHN technology invented by Dr. Milos Popovic, Director at UHN’s KITE Research Institute, MyndTec Inc. is currently working to develop MyndMoveTM – a commercialized product that delivers electrical stimulation to paralyzed muscles reproducing movement in arms and hands and has a sponsored research agreement with UHN to expand the applications of this technology.

The innovative...

Read More

Krembil's annual report features commercialization partnership

December 01, 2021 /in Latest News

The latest issue of The Krembil, the official newsletter of the Krembil Research Institute (formerly the Toronto Western Research Institute) is now available. Research at Krembil is focused on finding innovative treatments and cures for chronic debilitating disorders, including arthritis and diseases of the brain and eyes.

Stories in this month’s issue include the launch of Krembil's latest annual report, titled “Science Powering Discovery”, which can be viewed here.  The 2021 annual report features our commercialization partnership with Lucid Psycheceuticals -...

Read More

Drs. Daniel De Carvalho and Scott Bratman named joint Inventor of the Year

November 29, 2021 /in Latest News

Daniel De Carvalho & Scott Bratman, 2021 Inventors of the Year with Mark Taylor, Director, Commercialization at UHN. Dr. Scott Bratman is a radiation oncologist and internationally recognized expert in cell-free DNA and Dr. Daniel De Carvalho is a world-leading scholar in cancer epigenetics.

Commercialization at UHN is thrilled to recognize Princess Margaret Senior Scientists Drs. Daniel De Carvalho and Scott Bratman as... Read More

UHN start-up Treadwell Therapeutics announces US $91M Series B

November 18, 2021 /in Latest News

Treadwell Therapeutics' Series B set to fund clinical development of UHN's cancer fighting assets. 

Proceeds will fund the continued clinical development of CFI-400945, CFI-402257 and CFI-402411, the preclinical development of the Biologics and Cell Therapy platform. Financing led by Sino Biopharmaceutical and 3W Fund and includes other healthcare focused funds. 

"Our team is very excited to announce the closing of this transformative Series B financing, and are very grateful to our investors, both old and new, for their belief, commitment and support of our goal to build a globally impactful Biotechnology organization," said Shane Burgess, Chairman and co-CEO...

Read More

University Health Network reported top Canadian research commercialization institution for 2nd year running

November 01, 2021 /in Latest News


A summary of recent commercialization performance statistics for research at UHN.

According to the latest Association of University Technology Managers (AUTM) North American Annual Licensing Survey, the University Health Network (UHN) ranks as the #1 research commercialization institution in Canada for the second year running according to gross licensing revenue from the research it has...

Read More

Lucid Psycheceuticals Acquired by FSD Pharma to further develop UHN MS therapy platform

September 22, 2021 /in Latest News

“Congratulations to Lucid and FSD Pharma on taking this important step to accelerate potential treatment options for patients with multiple sclerosis based on technology developed at UHN. Working with our industry partners on moving our research forward means working together to create a healthier world,” says Mark Taylor, Director, Commercialization, University Health Network.

Full New Release: 

FSD Pharma, a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, recently announced completion of their previously announced acquisition of 100% of the issued...

Read More

Novo Nordisk acquires rights to UHN technology poised to advance heart health

July 12, 2021 /in Latest News

Pleased to announce that Novo Nordisk recently acquired rights to develop PRX004, a technology poised to advance the treatment of ATTR amyloidosis, a rare form of heart disease. First discovered at University Health Network by Dr. Avi Chakrabartty and his team, PRX004 has the potential to offer a new treatment option for this rare and often fatal disease where treatment options are currently lacking. Following successful Phase I clinical trials with our original licensee, Prothena Corporation plc, Novo Nordisk will now use its clinical expertise to develop PRX004 further, accelerating potential patient impact for this rare condition. Industry partnerships such as this help...

Read More

The Ontario government awards UHN over $3.8 million for cutting-edge research

July 08, 2021 /in Latest News

The Ontario government is providing over $70.4 million to support the development of homegrown ideas, products and technologies. Of these funds, $3.8 million has been provided to help advance research and innovation at UHN.

The funds were provided through two competitive programs from the Ontario Research Fund: the Early Researcher Award, which helps exceptional early career researchers to build their research teams, and the Research Infrastructure program, which enables the acquisition of advanced research infrastructure to conduct world-leading research. The projects that received funding are described below.

Early Researcher Awards
Three early career researchers at...

Read More

UHN launches start-up to advance blood-based precision medicine

June 22, 2021 /in Latest News

Adela, based on the cutting-edge work of two scientists at the Princess Margaret Cancer Centre, raises US$60 million in financing

A convenient blood test for cancer and other diseases could be on the horizon with Adela, a start-up company launched Wednesday out of UHN  that is poised to advance precision based, personalized medicine. Based on the cutting edge research of Drs. Daniel De Carvalho and Scott Bratman, both Senior Scientists at the Princess Margaret Cancer Centre, Adela envisions a future where multiple cancers – and other diseases  – could be detected by taking just a simple blood sample.

In the creation of Adela, Dr. Daniel De Carvalho,...

Read More

Lucid Psycheceuticals Announces Exclusive License to Develop Cutting-Edge Neurodegenerative Disease Therapeutics

June 14, 2021 /in Latest News

News Release: 

Lucid Psycheceuticals Inc. (Lucid), a psychedelics-inspired company focusing on total brain health, today announced that it has entered into a world-wide license agreement with University Health...

Read More